hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06374797, orgStudyIdInfo id: CMZ-207, briefTitle: A Study of Auxora in Patients With AKI and Injurious Lung "Crosstalk", acronym: KOURAGE, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2025-08, completionDateStruct date: 2025-08, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: CalciMedica, Inc., class: INDUSTRY, descriptionModule briefSummary: Approximately 150 patients with acute kidney injury (AKI) associated with acute hypoxemic respiratory failure (AHRF) will be randomized at up to 40 sites. Patients will be randomly assigned to either Auxora or matching placebo. Study drug infusions will occur every 24 hours for five consecutive days for a total of five infusions., conditionsModule conditions: Acute Kidney Injury, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 150, type: ESTIMATED, armsInterventionsModule interventions name: Auxora, interventions name: Placebo, outcomesModule primaryOutcomes measure: Days alive, ventilator-free and kidney replacement therapy (KRT)-free from SFISD through Day 30, secondaryOutcomes measure: Major adverse kidney event (MAKE) 90-1: ≥25% decline in estimated glomerular filtration rate (eGFR) from baseline, incident KRT, and all-cause mortality at 90 days, secondaryOutcomes measure: MAKE 90-2: ≥35% decline in eGFR from baseline, incident KRT, and all-cause mortality at 90 days, secondaryOutcomes measure: Proportion of patients alive at Day 30, secondaryOutcomes measure: Proportion of patients alive at Day 90, secondaryOutcomes measure: Days alive and ventilator-free from start of first infusion of study drug (SFISD) through Day 30, secondaryOutcomes measure: Days alive and KRT-free from SFISD through Day 30, secondaryOutcomes measure: Proportion of patients recovered from AHRF through Day 30 as categorized by an 8-point ordinal scale, secondaryOutcomes measure: Proportion of patients receiving KRT at Day 30, secondaryOutcomes measure: Proportion of patients receiving KRT at Day 90, secondaryOutcomes measure: Number of patients with treatment-related adverse events (TEAE), secondaryOutcomes measure: Number of patients with grade 3 TEAEs, otherOutcomes measure: Days alive and not hospitalized through Day 30, otherOutcomes measure: Proportion of patients re-hospitalized through Day 30, otherOutcomes measure: Proportion of patients re-hospitalized through Day 90, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06374784, orgStudyIdInfo id: perio2023ARP, briefTitle: Autogenous Demineralized Dentin Graft Combined With Injectable PRF + Metronidazole Versus Autogenous Demineralized Dentin Graft Combined With Injectable PRF Versus Autogenous Demineralized Dentin Graft Alone for Alveolar Ridge Preservation, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-20, primaryCompletionDateStruct date: 2024-10-20, completionDateStruct date: 2024-11-20, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-23, sponsorCollaboratorsModule leadSponsor name: Cairo University, class: OTHER, descriptionModule briefSummary: The aim of this trial is to compare the effect of autogenous demineralized dentin graft combined with injectable PRF loaded with metronidazole (sticky demineralized tooth releasing metronidazole) versus autogenous demineralized dentin graft combined with injectable PRF (sticky demineralized tooth) versus autogenous demineralized dentin graft (ADDG) alone on alveolar ridge preservation after extraction of non restorable, infected single-rooted teeth, conditionsModule conditions: Alveolar Bone Loss, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Alveolar ridge preservation using autogenous demineralized dentin graft combined with injectable PRF loaded with metronidazole, interventions name: Alveolar ridge preservation using autogenous demineralized dentin graft combined with injectable PRF, interventions name: Alveolar ridge preservation using autogenous demineralized dentin graft alone, outcomesModule primaryOutcomes measure: Alveolar ridge apico-coronal height change in mm, secondaryOutcomes measure: Alveolar ridge bucco-lingual width change in mm, secondaryOutcomes measure: Histological assessment, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: Faculty of Dentistry, city: Cairo, country: Egypt, contacts name: Cairo University, role: CONTACT, geoPoint lat: 30.06263, lon: 31.24967, hasResults: False
protocolSection identificationModule nctId: NCT06374732, orgStudyIdInfo id: TY2024002, briefTitle: The Benefits of a High-intensity Interval Training Intervention Delivered in a School Setting Among Adolescents, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-26, primaryCompletionDateStruct date: 2024-10-01, completionDateStruct date: 2024-10-01, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: University of Exeter, class: OTHER, collaborators name: China Scholarship Council, collaborators name: Ningbo University, descriptionModule briefSummary: A 12-week school-based high-intensity interval training intervention, with 8 classes of year 7 students randomly allocated to either intervention or control group. The interval training sessions will last for 6 to 10 minutes and will be delivered 5 times per week. Outcome variables will be physical activity, body composition, cardiorespiratory fitness, muscular strength, bone health, executive function, mental wellbeing, and academic performance, which will be measured pre- and post-intervention and two months after the intervention has been completed., conditionsModule conditions: Healthy, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 400, type: ESTIMATED, armsInterventionsModule interventions name: High-intensity interval training, interventions name: Control group, outcomesModule primaryOutcomes measure: Cardiorespiratory fitness, secondaryOutcomes measure: Muscular strength, secondaryOutcomes measure: Wellbeing, secondaryOutcomes measure: Enjoyment, secondaryOutcomes measure: Motivation, secondaryOutcomes measure: Affect, secondaryOutcomes measure: Academic performance, secondaryOutcomes measure: Height, secondaryOutcomes measure: Weight, secondaryOutcomes measure: BMI, secondaryOutcomes measure: Waist circumference, secondaryOutcomes measure: Body fat percentage, secondaryOutcomes measure: Physical activity, secondaryOutcomes measure: Bone health, secondaryOutcomes measure: Perceived physical ability, secondaryOutcomes measure: Flanker task, secondaryOutcomes measure: Visual 2-back task, secondaryOutcomes measure: Colour-shape switch task, otherOutcomes measure: Confounding variables, otherOutcomes measure: Interview, eligibilityModule sex: ALL, minimumAge: 11 Years, maximumAge: 13 Years, stdAges: CHILD, contactsLocationsModule locations facility: University of Exeter, status: RECRUITING, city: Exeter, state: Devon, zip: EX1 2LU, country: United Kingdom, contacts name: Yong Liu, role: CONTACT, phone: +447570013632, email: yl932@exeter.ac.uk, contacts role: CONTACT, phoneExt: Liu, email: yl932@exeter.ac.uk, contacts name: yong Liu, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 50.7236, lon: -3.52751, hasResults: False
protocolSection identificationModule nctId: NCT06374719, orgStudyIdInfo id: WiTNNess, briefTitle: WiTNNess - TNNT1 Myopathy Natural History Study, acronym: WiTNNess, statusModule overallStatus: RECRUITING, startDateStruct date: 2018-09-23, primaryCompletionDateStruct date: 2027-01-01, completionDateStruct date: 2027-06-01, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Clinic for Special Children, class: OTHER, descriptionModule briefSummary: WiTNNess is designed to accurately document the natural course and variation of muscle disease caused by pathogenic changes of the TNNT1 gene. The primary aim of the study is to specify meaningful outcome measures for future clinical trials. WiTNNess is open to children and adults worldwide. Participants can choose to include their information once (cross-sectional cohort) or every few months (prospective cohort)., conditionsModule conditions: TNNT1-associated Myopathy, conditions: Infantile-onset Nemaline Rod Myopathy, conditions: Myopathies, Nemaline, conditions: Myopathy, conditions: Myopathy, Rod, conditions: Myopathy; Hereditary, conditions: Amish Nemaline Myopathy, conditions: Nemaline Myopathy 5, conditions: NEM5, conditions: Genetic Muscle Disease, conditions: Recessive Hereditary Disorder (Autosomal), conditions: ANM, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Event-free survival, secondaryOutcomes measure: Motor Milestones, secondaryOutcomes measure: Thriving, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Clinic for Special Children, status: RECRUITING, city: Strasburg, state: Pennsylvania, zip: 17579, country: United States, contacts name: Joelle FS Williamson, MPH, role: CONTACT, phone: 717-687-9407, email: jwilliamson@clinicforspecialchildren.org, geoPoint lat: 39.98316, lon: -76.18412, hasResults: False
protocolSection identificationModule nctId: NCT06374706, orgStudyIdInfo id: 23-0129, briefTitle: Effects of End-Effector Type Rehabilitation Robots-Morning Walk on Symmetrical Walking Patterns in Individuals With Hemiparesis, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2025-04-01, completionDateStruct date: 2025-08-30, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: The University of Texas Medical Branch, Galveston, class: OTHER, descriptionModule briefSummary: In this study, our objective is to explore and evaluate interventions to improve the process of recovery following a stroke. The main focus is on enhancing symmetrical walking patterns in adults who have experienced neurological deficits due to a stroke. The primary tool will be an end-effector type rehabilitation robot, the Morning Walk®. This robot has been specifically designed to assist in enhancing symmetrical walking patterns for individuals recovering from a stroke Morning Walk® has received approval from the FDA, meaning it meets stringent safety and efficacy standards., conditionsModule conditions: Stroke, conditions: Healthy Volunteers, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Morning Walk training for stroke, interventions name: Morning Walk training for healthy, outcomesModule primaryOutcomes measure: The Number of Participants with Kinematic representation of the temporal events during end-effector robot training, primaryOutcomes measure: Muscle Activity in the lower extremities, primaryOutcomes measure: Spatiotemporal Patterns of Walking, Speeds, primaryOutcomes measure: Spatiotemporal Patterns of Walking, Parameters, eligibilityModule sex: ALL, minimumAge: 20 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of Texas Medical Branch, city: Galveston, state: Texas, zip: 77555, country: United States, contacts name: Mansoo Ko, Ph.D., role: CONTACT, phone: 409-772-9555, email: mako@utmb.edu, contacts name: Judith L Linton, MS, role: CONTACT, phone: 4092661767, email: jllinton@utmb.edu, geoPoint lat: 29.30135, lon: -94.7977, hasResults: False
protocolSection identificationModule nctId: NCT06374680, orgStudyIdInfo id: C3 ectomy, briefTitle: C3 Laminectomy With Cervical Laminoplasty, statusModule overallStatus: WITHDRAWN, startDateStruct date: 2017-03-20, primaryCompletionDateStruct date: 2021-12-31, completionDateStruct date: 2021-12-31, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-22, sponsorCollaboratorsModule leadSponsor name: Seoul National University Hospital, class: OTHER, descriptionModule briefSummary: 1. Background In cervical stenosis, cervical laminoplasty from the third to sixth cervical vertebrae is widely used. However, the muscles attached to the C2, which play an important role in the movement of our neck, are frequently damaged during the C3 laminoplasty. In contrast, cervical spine surgery through the removal of the C3 is thought to give less damage to the muscles attached to the C2.2. Purpose The aim of this study was to compare the prospective randomized comparison of these two surgical methods.3. Hypothesis There is no difference in the cervical length and overall cervical angle between 1 month, 3 months, 6 months, and 12 months postoperatively between C3 laminectomy with C4-6 laminoplasty and C3-6 laminoplasty., conditionsModule conditions: Neck Pain, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 0, type: ACTUAL, armsInterventionsModule interventions name: laminectomy at C3 level, outcomesModule primaryOutcomes measure: neck pain, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Seoul National University Hospital, city: Seoul, zip: 110-744, country: Korea, Republic of, geoPoint lat: 37.566, lon: 126.9784, hasResults: False
protocolSection identificationModule nctId: NCT06374654, orgStudyIdInfo id: 2023P003272, briefTitle: RCT of Home-based vs Formal Physical Therapy for Treatment of New Onset Non-insertional Achilles Tendinopathy, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2026-04, completionDateStruct date: 2026-04, studyFirstPostDateStruct date: 2024-04-18, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: Brigham and Women's Hospital, class: OTHER, descriptionModule briefSummary: The goal of this prospective randomized controlled trial is to compare the effectiveness of a home-based exercise protocol to formal physical therapy in patients who have been diagnosed with Achilles tendinopathy. The null hypothesis is that there will be no difference in the treatment outcomes between patients with Achilles tendinopathy who participate in a home-based program versus patients with Achilles tendinopathy who undergo formal physical therapy. Participants will be randomized to a 12-week home-based or formal physical therapy protocol and asked to complete brief outcomes surveys at their initial visit, and at 6 weeks, 12 weeks, 6 months, and 1 year after their initial visit., conditionsModule conditions: Achilles Tendinopathy, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 56, type: ESTIMATED, armsInterventionsModule interventions name: Home-based Exercise Protocol, interventions name: Formal Physical Therapy, outcomesModule primaryOutcomes measure: Victorian Institute of Sports Assessment self-administered Achilles questionnaire (VISA-A), secondaryOutcomes measure: PROMIS Pain Interference (4a), secondaryOutcomes measure: PROMIS Pain Intensity (3a), secondaryOutcomes measure: PROMIS Depression (4a), secondaryOutcomes measure: Patient Acceptable Symptom State Questionnaire, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Brigham and Women's Hospital, city: Boston, state: Massachusetts, zip: 02130, country: United States, geoPoint lat: 42.35843, lon: -71.05977, hasResults: False
protocolSection identificationModule nctId: NCT06374628, orgStudyIdInfo id: 0001, briefTitle: Pre-pectoral Tissue Expander and Acellular Dermal Matrix for a Two-stage Muscle Sparing Breast Reconstruction, statusModule overallStatus: RECRUITING, startDateStruct date: 2019-06-01, primaryCompletionDateStruct date: 2024-04-01, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-04-18, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: Rossella Elia, MD PhD, class: OTHER, descriptionModule briefSummary: The aim of the research is to evaluate clinical outcomes of a two stage muscle sparing prepectoral breast reconstruction using tissue expander (TE) entirely covered by an ADM. The authors aim to report surgical indications, technical tips, clinical and histological outcomes with the final objective of delineate a decision-making algorithm for immediate prosthetic breast reconstruction., conditionsModule conditions: Breast Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 44, type: ESTIMATED, armsInterventionsModule interventions name: breast reconstruction, outcomesModule primaryOutcomes measure: Patient satisfaction, secondaryOutcomes measure: Pain Evaluation, otherOutcomes measure: Complication rate, eligibilityModule sex: FEMALE, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: AOU Policlinico, status: RECRUITING, city: Bari, state: BA, country: Italy, contacts name: Rossella Elia, role: CONTACT, phone: 3409616476, email: rossellaelia4@gmail.com, geoPoint lat: 41.11148, lon: 16.8554, hasResults: False
protocolSection identificationModule nctId: NCT06374615, orgStudyIdInfo id: 2024-07, briefTitle: Insights Into Tick-Borne Diseases: a Study From an Endemic Area of Northern Italy, acronym: TICKTOC, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-25, primaryCompletionDateStruct date: 2029-03, completionDateStruct date: 2029-03, studyFirstPostDateStruct date: 2024-04-18, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: IRCCS Sacro Cuore Don Calabria di Negrar, class: OTHER, descriptionModule briefSummary: This is a monocentric, experimental, non-pharmacological and non-device no profit study.The study is experimental because all the visits and blood withdrawals foreseen by the protocol do not fall within the normal clinical practice., conditionsModule conditions: Tick-Borne Diseases, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 384, type: ESTIMATED, armsInterventionsModule interventions name: IgG and IgM search for specific Tick-Borne Patogens, outcomesModule primaryOutcomes measure: Number of individuals diagnosed with Tick-Borne Diseases (TBD) over the total number of individuals who were bitten by a tick which carried an identified TBP., secondaryOutcomes measure: Number of identified Tick-Borne Patogenees (TBPs) on the total number of analyzed ticks, secondaryOutcomes measure: Number of individuals who developed symptoms and were diagnosed for a TBP infection during the 12 weeks' follow-up period, secondaryOutcomes measure: Number of individuals who developed specific antibodies against a TBP after tick bite., secondaryOutcomes measure: List of novel TBPs that were not previously found in the study areas., eligibilityModule sex: ALL, minimumAge: 8 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: IRCCS Sacro Cuore Don Calabria hospital, status: RECRUITING, city: Negrar, state: Verona, zip: 37024, country: Italy, contacts name: Andrea Tedesco, role: CONTACT, email: andrea.tedesco@sacrocuore.it, contacts name: Andrea Tedesco, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 45.52918, lon: 10.93899, hasResults: False
protocolSection identificationModule nctId: NCT06374602, orgStudyIdInfo id: 33, briefTitle: Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-25, primaryCompletionDateStruct date: 2026-03-25, completionDateStruct date: 2026-06-25, studyFirstPostDateStruct date: 2024-04-18, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: Saint Petersburg State University, Russia, class: OTHER, descriptionModule briefSummary: This pilot phase 2 study evaluate the effectiveness and safety of pembrolizumab and lenvatinib in patients with anaplastic thyroid cancer. Patients with anaplastic thyroid cancer who are treatment-naive (BRAF-negative) and who were previously treated with chemptherapy or targeted therapy are scheduled to undergo pembrolizumab and lenvatinib and evaluate the outcomes according to the primary and secondary endpoints., conditionsModule conditions: Anaplastic Thyroid Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Pembrolizumab + Lenvatinib, outcomesModule primaryOutcomes measure: Objective response rate, primaryOutcomes measure: Progression-Free Survival, primaryOutcomes measure: Safety and Tolerability assessment (Incidence of Treatment-Emergent Adverse Events), secondaryOutcomes measure: Overall survival, secondaryOutcomes measure: The assessment of conversion to resectability, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Saint Petersburg State University Hospital, status: RECRUITING, city: Saint Petersburg, zip: 190020, country: Russian Federation, contacts name: Ernest Dzhelialov, role: CONTACT, phone: +7(911)134-50-44, email: ernest.dzhelialov@gmail.com, geoPoint lat: 59.93863, lon: 30.31413, hasResults: False